<?xml version="1.0" encoding="UTF-8"?>
<p>Chloroquine was first developed in the 1940s, as an aminoquinolone derivative developed for the treatment of malaria (
 <xref rid="ref17" ref-type="bibr">17</xref>). The chemical formula of chloroquine is C
 <sub>18</sub>H
 <sub>6</sub>CIN
 <sub>3</sub>. Chloroquine was granted FDA approval on October 31, 1949 (FDA, Approved Drug Products: Aralen Chloroquine Oral Tablets). Chloroquine and its derivative, hydroxychloroquine, are very closely related and used to treat malaria and rheumatologic conditions, respectively. Hydroxychloroquine is a disease-modifying anti-rheumatic drug, and it regulates the activity of the immune system, which may be overactive in some conditions including rheumatoid arthritis, discoid and systemic lupus erythematosus, and juvenile idiopathic arthritis. Chloroquine and hydroxychloroquine have been repurposed for the treatment of several disease conditions, including HIV, Systemic lupus erythematosus, and rheumatoid arthritis (
 <xref rid="ref18" ref-type="bibr">18</xref>). Chloroquine is classified as an anti-malarial drug and has shown potential in the treatment of avian influenza A (
 <xref rid="ref19" ref-type="bibr">19</xref>). Chloroquine has been indicated to treat infections caused by 
 <italic>P. vivax</italic>, 
 <italic>P. malariae</italic>, 
 <italic>P. ovale</italic>, and 
 <italic>P. falciparum</italic>. It can also be used to treat extraintestinal amebiosis (FDA; Approved Drug Products: Chloroquine Phosphate Oral tablets) and prophylaxis caused by Zika virus (
 <xref rid="ref20" ref-type="bibr">20</xref>, 
 <xref rid="ref21" ref-type="bibr">21</xref>).
</p>
